<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071499</url>
  </required_header>
  <id_info>
    <org_study_id>H09-03286</org_study_id>
    <nct_id>NCT01071499</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Oral Morphine and Pharmacogenomics of CYP2D6 and UGT2B7, in an Urban Pediatric Population Presenting for Elective Surgery</brief_title>
  <official_title>Pharmacokinetics of Oral Morphine and Pharmacogenomics of CYP2D6 and UGT2B7, in an Urban Pediatric Population (2 - 6 Years of Age) Presenting for Elective Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify and collect samples from children who have taken a&#xD;
      single oral dose of the pain medication morphine, and to determine the genetic differences in&#xD;
      the way children metabolize (break down in the body and how it affects them) morphine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      Oral morphine will produce more reliable peak plasma morphine concentrations and more&#xD;
      reliable analgesia than codeine, which is currently the drug of choice.&#xD;
&#xD;
      Background:&#xD;
&#xD;
      Codeine is the most commonly used oral opiate for analgesia in children. Codeine is a&#xD;
      pro-drug that requires activation by the isozyme CYP2D6. Genetically determined variations in&#xD;
      the activity of CYP2D6 can result in inappropriately low analgesic efficacy due to inadequate&#xD;
      conversion of the drug in &quot;poor-metabolizers&quot; and conversely, adverse reactions such as&#xD;
      respiratory depression and death in &quot;ultra-metabolizers&quot;. In some ethnic groups as many as&#xD;
      40% of patients may be susceptible to concentration-dependent toxicity from greater than&#xD;
      expected metabolism of codeine to morphine. We hypothesize that oral morphine is a feasible&#xD;
      and safe alternative to codeine. The primary aim of this study is to define and trial an&#xD;
      appropriate dose of morphine to provide children with effective and reliable perioperative&#xD;
      analgesia with a minimum risk of adverse drug effects. A secondary aim is to investigate the&#xD;
      pharmacogenetics of codeine and morphine metabolism in children.&#xD;
&#xD;
      Specific Objectives:&#xD;
&#xD;
      The pharmacokinetic properties of 3 (0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg) doses of oral&#xD;
      morphine will be described. We will determine the dose of oral morphine that results in a&#xD;
      peak plasma concentration that occurs within 60 - 90 min and results in the analgesic&#xD;
      therapeutic range (10 - 40 ng/mL). Pharmacogenetic profiles for two key enzymes involved in&#xD;
      codeine and morphine metabolism (CYP2D6 and UGT2B7) will be determined.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      After obtaining institutional review board approval, and written parental informed consent,&#xD;
      we will recruit 45 children for Phase I aged 2-6 years undergoing elective surgery. A&#xD;
      perceived ethnicity questionnaire will also be administered. Subjects recruited for Phase I&#xD;
      will be block assigned to one of the three doses of morphine. In Phase I, sampling will be&#xD;
      done for 4 hrs to determine the key pharmacokinetic parameters including Tmax, Cmax and AUC.&#xD;
      Monitoring will occur throughout and analgesic efficacy and adverse effects will be measured&#xD;
      post-operatively. All subjects will receive 24 hr telephone follow up for analgesic efficacy&#xD;
      and adverse drug effects.&#xD;
&#xD;
      Data Analysis: All continuous parametric data (weight, age, BMI) will be analyzed using&#xD;
      t-tests. Non-parametric ordinal data such as pain scores will be analyzed by the Mann-Whitney&#xD;
      U test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 mL blood sample will be obtained at 30, 60, 90, 120, 180 and 240 min after morphine administration.</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Face, Legs, Activity, Cry and Consolability (FLACC) pain score</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>One dose of morphine (0.1 mg/kg)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>One dose of morphine (0.2 mg/kg)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>One dose of morphine (0.3 mg/kg)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  2 - 6 years of age&#xD;
&#xD;
          -  ASA 1 &amp; 2 elective surgical patients - Procedures requiring opioid analgesia - Minimal&#xD;
             hospital stay of 4 hrs&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy or adverse reaction to morphine&#xD;
&#xD;
          -  Contraindication to morphine analgesia, such as a potential difficult airway --&#xD;
             Abnormal hepatic or renal function known by history or available laboratory results&#xD;
&#xD;
          -  Current regular opioid use&#xD;
&#xD;
          -  Surgical or anesthetic contraindication to oral premedication such as&#xD;
             gastro-esophageal reflux disease&#xD;
&#xD;
          -  Children with a BMI of &lt;10'ile or &gt;90'ile&#xD;
&#xD;
          -  Declines study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyne Montgomery, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gillian Lauder, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katherine Brand, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Carleton, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gideon Koren, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Rider, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>British Columbia Children's Hospital-Dept of Anesthesia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Carolyne Montgomery</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacogenetics</keyword>
  <keyword>morphine</keyword>
  <keyword>children</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

